| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Platyconic acid A does not have a defined biological target. It exhibits anti-inflammatory, antioxidant, and immunomodulatory activities. It may modulate signaling pathways such as NF-κB and MAPK, which are involved in inflammation. It is a triterpenoid saponin from Platycodon grandiflorus.
|
|---|---|
| ln Vitro |
Platyconic Acid A (0.5~2 μM; 30 minutes; A549 cells) inhibits PMA-induced phosphorylation of NF-κB p65, phosphorylation and degradation of IκBα, and phosphorylation of Akt in a concentration-dependent manner[1].
Platyconic Acid A (0.5~2 μM; 24 hours; A549 cells) reduces the concentration-dependent increase in MUC5AC mRNA expression caused by PMA[1]. In vitro, platyconic acid A exhibits anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in immune cells. It also shows antioxidant activity by scavenging free radicals. It is used in research to study the pharmacological properties of Platycodon grandiflorus. |
| ln Vivo |
Platyconic acid A is not a pharmacologically approved drug. It is a natural product and research compound with anti-inflammatory and antioxidant activities. It has not been evaluated in clinical trials.
|
| Enzyme Assay |
In vitro assays for platyconic acid A typically involve anti-inflammatory and antioxidant activity measurements. A standard protocol for anti-inflammatory activity involves culturing macrophages and stimulating them with LPS in the presence of varying concentrations of platyconic acid A (typically 1-100 µM). Cytokine production is measured by ELISA.
|
| Cell Assay |
Cell Types: A549 cells
Tested Concentrations: 0.5~2 μM Incubation Duration: 30 minutes Experimental Results: Inhibited PMA-induced NF-κB p65 phosphorylation, IκBα phosphorylation and degradation and Akt phosphorylation in a concentration-dependent manner. In vitro cell culture experiments with platyconic acid A typically involve immune cells. Cells are cultured in appropriate media and treated with the compound at concentrations ranging from 1-100 µM for 24 hours. Cytokine production, cell viability, and signaling pathways are measured. |
| Animal Protocol |
In vivo animal studies with platyconic acid A are not well documented. It is used primarily as a research compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of platyconic acid A are not characterized, as it is not a drug substance. The compound is not intended for human exposure.
|
| Toxicity/Toxicokinetics |
Platyconic acid A may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood.
|
| References | |
| Additional Infomation |
Platycolic acid A is a triterpenoid saponin that acts as a metabolite. Platycolic acid A has been discovered in Platycodon grandiflorus, and relevant data have been reported.
Platyconic acid A is a triterpenoid saponin from Platycodon grandiflorus with anti-inflammatory and antioxidant activities. It has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C57H90O29
|
|---|---|
| Molecular Weight |
1239.31
|
| Exact Mass |
1238.556
|
| CAS # |
68051-23-0
|
| PubChem CID |
70698300
|
| Appearance |
White to off-white solid
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.663
|
| LogP |
-0.36
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
29
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
86
|
| Complexity |
2470
|
| Defined Atom Stereocenter Count |
32
|
| SMILES |
O([C@@H]1[C@H]([C@@H]([C@H]([C@H](CO)O1)O)O)O)[C@@H]1[C@@H](C[C@]2(C)[C@@H]([C@@]1(C(=O)O)CO)CC[C@]1(C)[C@@]3(C)C[C@@H]([C@]4(C(=O)O[C@@H]5[C@H]([C@@H]([C@@H](CO5)O)O)O[C@@H]5[C@H]([C@H]([C@@H]([C@@H](C)O5)O[C@@H]5[C@H]([C@@H]([C@H](CO5)O)O[C@@H]5[C@H]([C@](CO)(CO5)O)O)O)O)O)CCC(C)(C)C[C@@H]4C3=CC[C@H]12)O)O
|
| InChi Key |
MMBAMPXMNQQFQO-JQIGHYGPSA-N
|
| InChi Code |
InChI=1S/C57H90O29/c1-22-39(82-44-38(71)40(27(63)18-77-44)83-48-42(72)55(76,19-59)21-79-48)35(68)37(70)45(80-22)84-41-32(65)26(62)17-78-47(41)86-50(75)56-12-11-51(2,3)13-24(56)23-7-8-29-52(4)14-25(61)43(85-46-36(69)34(67)33(66)28(16-58)81-46)57(20-60,49(73)74)30(52)9-10-53(29,5)54(23,6)15-31(56)64/h7,22,24-48,58-72,76H,8-21H2,1-6H3,(H,73,74)/t22-,24-,25-,26-,27+,28+,29+,30+,31+,32-,33+,34-,35-,36+,37+,38+,39-,40-,41+,42-,43-,44-,45-,46-,47-,48-,52+,53+,54+,55+,56+,57+/m0/s1
|
| Chemical Name |
(2S,3R,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-[(2S,3R,4S,5S)-3-[(2S,3R,4S,5R,6S)-5-[(2S,3R,4S,5R)-4-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxycarbonyl-2,8-dihydroxy-4-(hydroxymethyl)-6a,6b,11,11,14b-pentamethyl-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid
|
| Synonyms |
Platyconic acid A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 25 mg/mL (20.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8069 mL | 4.0345 mL | 8.0690 mL | |
| 5 mM | 0.1614 mL | 0.8069 mL | 1.6138 mL | |
| 10 mM | 0.0807 mL | 0.4035 mL | 0.8069 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
